ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 490

A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis – an Interim Analysis

Stephen Oakley1,2,3, Niloofar Esmaili4, Gabor Major4, David Mathers4,5, Siva Ratnarajah6, John van der Kallen5, Mark Collins6, Marc Toh6 and John Glass4, 1Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, 2School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, 3Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, 4Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, 5Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, 6Rheumatology, Private Practice, Newcastle, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Biologic agents, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the onset of arthritis. Amongst RA patients Shared Epitope (SE) positivity is associated with increased CV mortality but it is unclear if this is mediated by inflammation. Observational studies suggest that TNF-inhibition improves endothelial dysfunction and lowers CV risk but RCT data are lacking. HEART-RA is a single-site RCT evaluating the effect of Humira upon endothelial function in ACPA positive RA.

Methods

ACPA positive RA patients with moderate disease activity were enrolled in a 24-week trial of Humira versus placebo on a background of usual care undergoing assessments of disease activity and endothelial function (reactive hyperaemic index – RHI) at baseline, 2, 4, 12 and 24 weeks. Serum lipids were evaluated when deemed appropriate by the treating clinician.  Improvements RHI in Humira and placebo arms were compared by t test. Secondary analysis evaluated influences upon RHI by univariate analysis and multivariate time-series regression modelling.

Results

23 subjects included 9 early (<6months) and 14 established RA underwent a total 138 assessments. 1 patient carried none, 10 one and 12 two SE. 12 patients (4 Humira and 3 placebo) withdrew after week 12 and were assessed open label at 24 weeks. HDL was available for 28 and LDL for 24. There were non-significant trends to greater RHI improvements in the Humira arm. Secondary analysis found better RHI in patients currently receiving Humira distinct from more general negative effects of higher disease activity and SE dose. Paradoxically ever-smokers had better RHI. Limited data suggested positive effects from HDL and negative from LDL. 

Conclusion

Several disease-specific factors appear to contribute to endothelial dysfunction in RA. RHI is clearly better in patients receiving Humira distinct from the broader effects of disease activity. The paradoxical effect of smoking is not consistent with previous studies and is likely due to the small number of patients. However, negative effects of the SE are consistent with previous work. Furthermore, the effect appears to be quite distinct from inflammatory mechanisms seen in RA and introducing the possible role of antigen processing and lipid transport with implications for subjects with Pre-RA and therapies that that adversely influence lipids.

Raw Adjusted
Input Variables Mean RHI   Mean RHI   Difference t test p value Difference  Adjusted p value           
Humira vs No Humira 2.23 2.11 0.12 0.016 0.19 0.041
3VDAS28CRP (<3.88 vs >3.88) 2.22 2.00 0.22 0.016 0.17 0.056
Shared Epitope (2 vs 0 or 1 copy) 2.20 2.04 0.16 0.080 0.25 0.045
Smoking (Ever versus Never) 2.20 1.79 0.24 0.001 0.44 0.004
Established vs Early RA 2.21 1.97 0.24 0.010 0.20 0.119
HDL Choilesterol (>1.20 vs <1.20)       2.23 2.06 0.17 0.448 Insufficient data
LDL Cholesterol (<3.00 vs >3.00) 2.13 2.07 0.06 0.226 Insufficient data

Disclosure:

S. Oakley,

Abbvie,

2,

UCB,

9,

Roche Pharmaceuticals,

9,

Janssen Pharmaceutica Product, L.P.,

9,

Pfizer Inc,

9;

N. Esmaili,

Abbvie Laboratories,

2;

G. Major,

Abbvie,

2,

Abbvie,

9;

D. Mathers,

Abbvie,

2,

Pfizer Inc,

9,

BMS,

9,

Abbvie,

9,

UCB,

9,

Janssen Pharmaceutica Product, L.P.,

9;

S. Ratnarajah,

Abbvie,

2;

J. van der Kallen,

Abbvie,

2,

Amgen,

8;

M. Collins,

Abbvie,

2,

BMS,

9,

Roche Pharmaceuticals,

9,

Abbvie,

9;

M. Toh,

Abbvie,

2;

J. Glass,

Abbvie,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomised-controlled-trial-evaluating-the-effect-of-humira-upon-endothelial-function-in-acpa-positive-rheumatoid-arthritis-ae-an-interim-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies